Search results for "STANDARD"

showing 10 items of 3299 documents

3D characterisation of the dynamics of foot joints of adults during walking. Gait pattern identification

2017

A detailed description of the kinematics and kinetics of the ankle, midtarsal and metatarsophalangeal joints of the feet of a healthy adult male population during barefoot walking is provided. Plots of the angles and moments in each plane during the stance phase are reported, along with the mean and standard deviation values of 87 different parameters that characterise the 3D dynamics of the foot joints. These parameters were used to check for similarities between subjects through a hierarchical analysis that allowed three different gait patterns to be identified, most of the differences corresponding to the frontal and transverse planes.

AdultMalemedicine.medical_specialtyPopulationBiomedical EngineeringMetatarsophalangeal jointsBioengineeringKinematicsStandard deviation03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationImaging Three-DimensionalFiducial MarkersFoot JointsmedicineCluster AnalysisHumansgait patternseducationGaitMathematicseducation.field_of_studyDynamics (mechanics)030229 sport sciencesGeneral MedicineAnatomydynamicsfoot jointsGaitComputer Science ApplicationsBiomechanical PhenomenaHuman-Computer InteractionTransverse planemedicine.anatomical_structurekinematicskineticsAnkle030217 neurology & neurosurgery
researchProduct

Prognostic effect of carbohydrate antigen 125-guided therapy in patients recently discharged for acute heart failure (CHANCE-HF). Study design.

2014

Abstract Introduction and objectives Morbidity and mortality after admission for acute heart failure remain prohibitively high. In that setting, plasma levels of antigen carbohydrate 125 have shown to correlate with the severity of fluid overload and the risk of mortality and readmission. Preliminary data suggests a potential role of antigen carbohydrate 125 to guide therapy. The objective of this study is to evaluate the prognostic effect of an antigen carbohydrate 125-guided management strategy vs standard therapy in patients recently discharged for acute heart failure. Methods This is a multicenter, randomized, single-blind, efficacy trial study of patients recently discharged from acute…

AdultMalemedicine.medical_specialtyRandomizationTime FactorsRisk AssessmentAntigenCause of DeathRisk of mortalityMedicineHumansIn patientSingle-Blind MethodProspective StudiesIntensive care medicineAgedHeart Failurebusiness.industryStandard treatmentDisease ManagementCardiovascular AgentsGeneral MedicineMiddle Agedmedicine.diseasePrognosisPatient DischargeClinical trialSurvival RateSpainHeart failureCA-125 AntigenAcute DiseaseFemalebusinessCarbohydrate antigenBiomarkersFollow-Up StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Inter- and intrarater reliability of two proprioception tests using clinical applicable measurement tools in subjects with and without knee osteoarth…

2017

Abstract Background The therapeutic value of proprioceptive-based exercises in knee osteoarthritis (KOA) management warrants investigation of proprioceptive testing methods easily accessible in clinical practice. Objective To estimate inter- and intrarater reliability of the knee joint position sense (KJPS) test and knee force sense (KFS) test in subjects with and without KOA. Design Cross-sectional test-retest design. Method Two blinded raters performed independently repeated measures of the KJPS and KFS test, using an analogue inclinometer and handheld dynamometer, respectively, in eight KOA patients (12 symptomatic knees) and 26 healthy controls (52 asymptomatic knees). Intraclass correl…

AdultMalemedicine.medical_specialtyRange of Motion Articular/physiologyIntraclass correlationPhysical Therapy Sports Therapy and RehabilitationOsteoarthritisMuscle Strength DynamometerKnee Joint03 medical and health sciencesDisability Evaluation0302 clinical medicinePhysical medicine and rehabilitationReference ValuesmedicineHumans030212 general & internal medicineRange of Motion ArticularReliability (statistics)Aged030203 arthritis & rheumatologyObserver VariationOsteoarthritis Knee/diagnosisbusiness.industryRepeated measures designIntra-rater reliabilityMiddle AgedOsteoarthritis Kneemedicine.diseaseProprioceptionKnee painStandard errorCross-Sectional StudiesPhysical therapyFemaleHuman medicinemedicine.symptombusinessProprioception/physiologyMusculoskeletal sciencepractice
researchProduct

Ureteral realignment with combined access as a treatment of complete ureteral transection.

2019

Ureteral realignment using a ureteral stent can be an alternative treatment in cases of complete ureteral transection and may avoid the need for reconstructive surgery. The combined access can help the passage of the guidewire through the injured area and the threading of the urinary system of the patient. We present a case of a 38-year-old man with multiples abdominal surgeries, who underwent a complete ureteral section treated with ureteral realignment with combined access. The subsequent evolution was favourable, with resolution of the ureteral injury at the acute time, and without the presence of long-term obstruction. Although we must accept that the standard treatment of the complete …

AdultMalemedicine.medical_specialtyReconstructive surgeryUrologyUrinary systemmedicine.medical_treatmentAnastomosisUreteral realignmenturologic and male genital diseaseslcsh:RC870-923Ureteral injurymedicineHumansbusiness.industryurogenital systemStandard treatmentTreatment optionsStentlcsh:Diseases of the genitourinary system. UrologyAlternative treatmentfemale genital diseases and pregnancy complicationsSurgeryUreteral traumasurgical procedures operativeUrologic Surgical ProceduresUreterbusinessEndourologyUreteral transectionArchivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
researchProduct

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.

2021

Summary Background Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell carcinoma and has shown clinical activity as monotherapy in first-line non-small-cell lung cancer. Here, we present the primary analysis data of cemiplimab in patients with locally advanced basal cell carcinoma after HHI therapy. Methods We did an open-label, multicentre, single-arm, phase 2 trial across 38 outpatient clinics, primarily at academic medical centres, in Canada, Europe, and the USA. Eligible patients (aged ≥18 years…

AdultMalemedicine.medical_specialtySkin NeoplasmsPyridinesProgrammed Cell Death 1 ReceptorVismodegibAntibodies Monoclonal Humanized030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaClinical endpointOutpatient clinicHumansBasal cell carcinomaAnilidesHedgehog ProteinsLung cancerImmune Checkpoint InhibitorsAgedbusiness.industryStandard treatmentMiddle Agedmedicine.diseaseRegimenOncologyCarcinoma Basal CellDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalSettore MED/35 - MALATTIE CUTANEE E VENEREEbusinessmedicine.drugThe Lancet. Oncology
researchProduct

Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks

2011

Guidelines recommend that patients with chronic hepatitis C virus (HCV) infection be treated with pegylated interferon and ribavirin for 24, 48, or 72 weeks, based on their virologic response to treatment. We investigated the effects of treating patients for individualized durations.We treated 398 treatment-naïve patients who had HCV genotype 1 infections with pegylated interferon alfa-2b and ribavirin for 24, 30, 36, 42, 48, 60, or 72 weeks (mean of 39 weeks, termed individualized therapy); the duration of therapy was determined based on baseline viral load and the time point at which HCV RNA levels became undetectable (measured at weeks 4, 6, 8, 12, 24, and 30). Results were compared with…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentGenotypeTranscription-mediated amplificationHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyVirusPolyethylene GlycolsYoung AdultLiver diseasechemistry.chemical_compoundPegylated interferonGermanyInternal medicineRibavirinHumansMedicinePrecision MedicineAgedDose-Response Relationship DrugHepatologybusiness.industryStandard treatmentRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesClinical trialTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy CombinationFemalebusinessViral loadmedicine.drugGastroenterology
researchProduct

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic …

2007

SummaryTreatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge. Here we report on our experience with the monoclonal anti-CD20 antibody rituximab (R) compared to standard treatment in these diseases. Patients with non-familialTTP orAIHA and no underlying malignancy were included in our analysis. Safety and efficacy of R-treatment were compared to results obtained in standard treatment approaches. Altogether, 27 patients were analyzed, comprising 15 patients withTTP and 12 patients with AIHA. The patients’ average age at the time of diagnosis wa…

AdultMalemedicine.medical_specialtyTime FactorsThrombotic thrombocytopenic purpuraSalvage therapyGastroenterologyDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRecurrenceMedian follow-upGermanyhemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProgression-free survivalAgedRetrospective StudiesSalvage TherapyPurpura Thrombocytopenic Idiopathicbusiness.industryStandard treatmentAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeDrug Therapy CombinationFemaleRituximabAnemia Hemolytic AutoimmuneRituximabbusinessFollow-Up Studiesmedicine.drugThrombosis and Haemostasis
researchProduct

Evaluation of urodynamic studies by computer

1978

In an attempt to simplify urodynamic evaluation, the data obtained from cystometry, urethral profile and flowmetry were analysed using the ICS recommendations for standardization and terminology. All studies were compiled from check lists feasible for computation. The aim was to establish standards and "typical" changes for the normal bladder and pathological states to enable automatic readout of computed data. The results did, in fact, show "typical" changes but failed to establish standard measurements suitable for completely computed diagnoses.

AdultMalemedicine.medical_specialtyUrethral ObstructionAdolescentStandardizationManometryUrologyUrinary BladderUrodynamic studiesTerminologyUrethraHydrostatic PressuremedicineHumansMedical physicsDiagnosis Computer-AssistedUrinary Bladder NeurogenicMedical diagnosisChildAgedmedicine.diagnostic_testElectromyographybusiness.industryInfantCystometryMiddle AgedSurgeryUrinary IncontinenceChild PreschoolNormal bladderFemalebusinessUrological Research
researchProduct

Comparison and interpretability of the available urticaria activity scores

2017

The urticaria activity score (UAS) is the gold standard for assessing disease activity in patients with chronic spontaneous urticaria (CSU). Two different versions, the UAS7 and UAS7TD , are currently used in clinical trials and routine care. To compare both versions and to obtain data on their interpretability, 130 CSU patients applied both versions and globally rated their disease activity as none, mild, moderate, or severe. UAS7 and UAS7TD values correlated strongly (r = .90, P < .001). Interquartile ranges for UAS7 and UAS7TD values for mild, moderate, and severe CSU were 11-20 and 10-24, 16-30 and 16-32, and 27-37 and 28-40. UAS7 values were slightly, but significantly lower as compare…

AdultMalemedicine.medical_specialtyUrticariaImmunologySeverity of Illness IndexMean differenceDisease activity030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineOutcome Assessment Health CaremedicineHumansImmunology and AllergyIn patientRoutine careInterpretabilitybusiness.industryReproducibility of ResultsGold standard (test)Middle AgedSurgeryClinical trial030228 respiratory systemFemalebusinessBiomarkersAllergy
researchProduct

The Urticaria Activity Score-Validity, Reliability, and Responsiveness.

2018

Background Chronic spontaneous urticaria is characterized by fluctuating symptoms. Its activity is assessed with the urticaria activity score (UAS). Two versions of the urticaria activity score used for 7 consecutive days (UAS7) are available: (1) The guideline-recommended UAS7, with once-daily documentation, and (2) the UAS7TD, with twice-daily documentation. Objective To better characterize both UAS7 versions with regard to their validity, reliability, sensitivity to change, minimal important difference (MID), and smallest detectable change (SDC). Methods One hundred thirty adult patients with chronic spontaneous urticaria completed both UAS7 versions, the Patients Global Assessment (PatG…

AdultMalemedicine.medical_specialtyUrticariaIntraclass correlationOmalizumabOmalizumabSeverity of Illness IndexDisease activity030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeimmune system diseasesInternal medicineAnti-Allergic AgentsImmunology and AllergyMedicineHumansskin and connective tissue diseasesReceiver operating characteristicbusiness.industryReproducibility of ResultsDermatology Life Quality IndexMiddle AgedStandard error030228 respiratory systemChronic DiseasePhysical therapyPatient-reported outcomeFemalebusinessmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct